I agree with your last statement; now that Gilenya is approved, new oral agents will presumably be tested head-to-head vs Gilinya, and new injectable agents can continue to be tested head-to-head vs any of several comparators.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”